{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:28:55Z","timestamp":1789586935362,"version":"build-2803163510"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-023-01853-z","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T02:02:16Z","timestamp":1705370536000},"page":"561-571","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcomes and management of kidney transplant recipients with Fabry disease: a review"],"prefix":"10.1093","volume":"37","author":[{"given":"Bo","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed G.","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5863-3562","authenticated-orcid":false,"given":"Sam","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"9","key":"1853_CR1","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1002\/mgg3.1163","volume":"8","author":"D Klingelhofer","year":"2020","unstructured":"Klingelhofer D, Braun M, Seeger-Zybok RK, Quarcoo D, Bruggmann D, Groneberg DA (2020) Global research on Fabry\u2019s disease: demands for a rare disease. Mol Genet Genomic Med 8(9):e1163","journal-title":"Mol Genet Genomic Med"},{"issue":"21","key":"1853_CR2","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry\u2019s disease Ceramidetrihexosidase deficiency. N Engl J Med 276(21):1163\u20131167","journal-title":"N Engl J Med"},{"issue":"4","key":"1853_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","volume":"138","author":"RJ Desnick","year":"2003","unstructured":"Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338\u2013346","journal-title":"Ann Intern Med"},{"issue":"4","key":"1853_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A et al (2018) Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416\u2013427","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1853_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","volume":"55","author":"D Doheny","year":"2018","unstructured":"Doheny D, Srinivasan R, Pagant S, Chen B, Yasuda M, Desnick RJ (2018) Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017. J Med Genet 55(4):261\u2013268","journal-title":"J Med Genet"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.gene.2017.10.064","volume":"641","author":"P Juchniewicz","year":"2018","unstructured":"Juchniewicz P, Kloska A, Tylki-Szymanska A, Jakobkiewicz-Banecka J, Wegrzyn G, Moskot M, Gabig-Ciminska M, Piotrowska E (2018) Female Fabry disease patients and X-chromosome inactivation. Gene 641:259\u2013264","journal-title":"Gene"},{"issue":"9813","key":"1853_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379(9813):335\u2013341","journal-title":"Lancet"},{"key":"1853_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/TCRM.S247814","volume":"16","author":"I Vardarli","year":"2020","unstructured":"Vardarli I, Rischpler C, Herrmann K, Weidemann F (2020) Diagnosis and screening of patients with fabry disease. Ther Clin Risk Manag 16:551\u2013558","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"1853_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1399-0004.2009.01345.x","volume":"77","author":"MA Barba-Romero","year":"2010","unstructured":"Barba-Romero MA, Deegan P, Giugliani R, Hughes D (2010) Does geographical location influence the phenotype of Fabry disease in women in Europe? Clin Genet 77(2):131\u2013140","journal-title":"Clin Genet"},{"issue":"1","key":"1853_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/cge.12613","volume":"89","author":"L Echevarria","year":"2016","unstructured":"Echevarria L, Benistan K, Toussaint A, Dubourg O, Hagege AA, Eladari D, Jabbour F, Beldjord C, De Mazancourt P, Germain DP (2016) X-chromosome inactivation in female patients with Fabry disease. Clin Genet 89(1):44\u201354","journal-title":"Clin Genet"},{"issue":"2","key":"1853_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000488121","volume":"43","author":"M Del Pino","year":"2018","unstructured":"Del Pino M, Andres A, Bernabeu AA, de Juan-Rivera J, Fernandez E, de Dios Garcia Diaz J, Hernandez D, Luno J, Fernandez IM, Paniagua J et al (2018) Fabry nephropathy: an evidence-based narrative review. Kidney Blood Press Res 43(2):406\u2013421","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"1853_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20(5):1132\u20131139","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1853_CR13","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/ndt\/gfy357","volume":"34","author":"CV Madsen","year":"2019","unstructured":"Madsen CV, Granqvist H, Petersen JH, Rasmussen AK, Lund AM, Oturai P, Sorensen SS, Feldt-Rasmussen U (2019) Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study. Nephrol Dial Transplant 34(9):1525\u20131533","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1853_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ndt\/gfx009","volume":"33","author":"A Pisani","year":"2018","unstructured":"Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, Bruzzese D, Feriozzi S, Imbriaco M, Tedeschi E, Cocozza S, De Rosa D, Mignani R et al (2018) Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant 33(2):318\u2013323","journal-title":"Nephrol Dial Transplant"},{"key":"1853_CR15","doi-asserted-by":"publisher","first-page":"205435812098562","DOI":"10.1177\/2054358120985627","volume":"8","author":"CAB Silva","year":"2021","unstructured":"Silva CAB, Moura-Neto JA, Dos Reis MA, Vieira Neto OM, Barreto FC (2021) Renal manifestations of Fabry disease: a narrative review. Can J Kidney Health Dis 8:2054358120985627","journal-title":"Can J Kidney Health Dis"},{"issue":"5","key":"1853_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","volume":"51","author":"C Tondel","year":"2008","unstructured":"Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51(5):767\u2013776","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1853_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7326\/0003-4819-77-2-195","volume":"77","author":"M Philippart","year":"1972","unstructured":"Philippart M, Franklin SS, Gordon A (1972) Reversal of an inborn sphingolipidosis (Fabry\u2019s disease) by kidney transplantation. Ann Intern Med 77(2):195\u2013200","journal-title":"Ann Intern Med"},{"key":"1853_CR18","doi-asserted-by":"crossref","unstructured":"(1975) Renal transplantation in congenital and metabolic diseases. A report from the ASC\/NIH renal transplant registry. JAMA 232(2):148\u2013153","DOI":"10.1001\/jama.232.2.148"},{"issue":"1 Pt 1","key":"1853_CR19","first-page":"57","volume":"13","author":"SE Maizel","year":"1981","unstructured":"Maizel SE, Simmons RL, Kjellstrand C, Fryd DS (1981) Ten-year experience in renal transplantation for Fabry\u2019s disease. Transplant Proc 13(1 Pt 1):57\u201359","journal-title":"Transplant Proc"},{"issue":"Suppl 7","key":"1853_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ndt\/11.supp7.4","volume":"11","author":"D Tsakiris","year":"1996","unstructured":"Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, Piccoli G, dos Santos JP, Tognoni G, Vanrenterghem Y, Report on management of renale failure in Europe, XXVI, 1995 et al (1996) Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11(Suppl 7):4\u201320","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1853_CR21","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","volume":"69","author":"A Ojo","year":"2000","unstructured":"Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B (2000) Excellent outcome of renal transplantation in patients with Fabry\u2019s disease. Transplantation 69(11):2337\u20132339","journal-title":"Transplantation"},{"issue":"2","key":"1853_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/TP.0b013e318191a842","volume":"87","author":"T Shah","year":"2009","unstructured":"Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S (2009) Kidney transplant outcomes in patients with Fabry disease. Transplantation 87(2):280\u2013285","journal-title":"Transplantation"},{"issue":"9","key":"1853_CR23","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.ekir.2021.06.013","volume":"6","author":"MS Ng","year":"2021","unstructured":"Ng MS, Malacova E, Hurst C, Johnson DW, Mallett AJ (2021) Clinical Outcomes of People With Fabry Disease-ANZDATA Registry Study. Kidney Int Rep 6(9):2481\u20132485","journal-title":"Kidney Int Rep"},{"issue":"11","key":"1853_CR24","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1097\/TP.0000000000002252","volume":"102","author":"S Ersozlu","year":"2018","unstructured":"Ersozlu S, Desnick RJ, Huynh-Do U, Canaan-Kuhl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S et al (2018) Long-term outcomes of kidney transplantation in Fabry disease. Transplantation 102(11):1924\u20131933","journal-title":"Transplantation"},{"key":"1853_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/diseases9010002","author":"MLG Suarez","year":"2020","unstructured":"Suarez MLG, Thongprayoon C, Hansrivijit P, Medaura J, Vaitla P, Mao MA, Bathini T, Boonpheng B, Kanduri SR, Kovvuru K et al (2020) Outcomes of kidney transplantation in Fabry disease: a meta-analysis. Diseases. https:\/\/doi.org\/10.3390\/diseases9010002","journal-title":"Diseases"},{"issue":"5870","key":"1853_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/bmj.3.5870.28","volume":"3","author":"FR Buhler","year":"1973","unstructured":"Buhler FR, Thiel G, Dubach UC, Enderlin F, Gloor F, Tholen H (1973) Kidney transplantation in Fabry\u2019s disease. Br Med J 3(5870):28\u201329","journal-title":"Br Med J"},{"issue":"7","key":"1853_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1177\/014107688207500716","volume":"75","author":"M Clement","year":"1982","unstructured":"Clement M, McGonigle RJ, Monkhouse PM, Keogh AM, Marten RH, Bewick M, Parsons V (1982) Renal transplantation in Anderson-Fabry disease. J R Soc Med 75(7):557\u2013560","journal-title":"J R Soc Med"},{"issue":"2","key":"1853_CR28","first-page":"287","volume":"10","author":"H Gantenbein","year":"1995","unstructured":"Gantenbein H, Bruder E, Burger HR, Briner J, Binswanger U (1995) Recurrence of Fabry\u2019s disease in a renal allograft 14 years after transplantation. Nephrol Dial Transplant 10(2):287\u2013289","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"1853_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJM197212142872402","volume":"287","author":"JT Clarke","year":"1972","unstructured":"Clarke JT, Guttmann RD, Wolfe LS, Beaudoin JG, Morehouse DD (1972) Enzyme replacement therapy by renal allotransplantation in Fabry\u2019s disease. N Engl J Med 287(24):1215\u20131218","journal-title":"N Engl J Med"},{"issue":"8","key":"1853_CR30","doi-asserted-by":"publisher","first-page":"e361","DOI":"10.1097\/TP.0000000000002257","volume":"102","author":"A Likhitsup","year":"2018","unstructured":"Likhitsup A, Helzberg JH, Alba LM, Larkin MK, Cummings LS, Island ER, Lustig RM, Forster J (2018) Persistent Alpha-galactosidase A Deficiency After Simultaneous Liver-kidney Transplantation in a Patient With Fabry Disease. Transplantation 102(8):e361","journal-title":"Transplantation"},{"issue":"5","key":"1853_CR31","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1093\/ndt\/gfm813","volume":"23","author":"R Mignani","year":"2008","unstructured":"Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA et al (2008) Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 23(5):1628\u20131635","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1853_CR32","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.ymgme.2015.12.406","volume":"117","author":"LF Pineda-Galindo","year":"2016","unstructured":"Pineda-Galindo LF, Moranchel-Garc\u00eda L (2016) Beneficial effect of agalsidase beta on long term evolution of patients with Fabry disease and kidney transplant. Mol Genet Metab 117(2):S95","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1853_CR33","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/j.1523-1755.2004.00514.x","volume":"65","author":"R Mignani","year":"2004","unstructured":"Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, Moneti G, Cagnoli L (2004) Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int 65(4):1381\u20131385","journal-title":"Kidney Int"},{"key":"1853_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12883-016-0590-7","volume":"16","author":"Y Schuller","year":"2016","unstructured":"Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M (2016) Erratum to: pain management strategies for neuropathic pain in Fabry disease-a systematic review. BMC Neurol 16:67","journal-title":"BMC Neurol"},{"key":"1853_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","volume":"16","author":"Y Schuller","year":"2016","unstructured":"Schuller Y, Linthorst GE, Hollak CE, Van Schaik IN, Biegstraaten M (2016) Pain management strategies for neuropathic pain in Fabry disease\u2013a systematic review. BMC Neurol 16:25","journal-title":"BMC Neurol"},{"key":"1853_CR36","doi-asserted-by":"publisher","first-page":"924710","DOI":"10.3389\/fnut.2022.924710","volume":"9","author":"G Bertoldi","year":"2022","unstructured":"Bertoldi G, Carraro G, Ravarotto V, Di Vico V, Baldini Anastasio P, Vitturi N, Francini F, Stefanelli LF, Calo LA (2022) The effect of green tea as an adjuvant to enzyme replacement therapy on oxidative stress in fabry disease: a pilot study. Front Nutr 9:924710","journal-title":"Front Nutr"},{"issue":"11","key":"1853_CR37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/jhg.2016.78","volume":"61","author":"JH Kim","year":"2016","unstructured":"Kim JH, Lee BH, Hyang Cho J, Kang E, Choi JH, Kim GH, Yoo HW (2016) Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet 61(11):923\u2013929","journal-title":"J Hum Genet"},{"key":"1853_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M (2015) Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment. Orphanet J Rare Dis 10:125","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1853_CR39","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10545-014-9724-5","volume":"37","author":"JM Itier","year":"2014","unstructured":"Itier JM, Ret G, Viale S, Sweet L, Bangari D, Caron A, Le-Gall F, Benichou B, Leonard J, Deleuze JF et al (2014) Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis 37(6):1013\u20131022","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"1853_CR40","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00228-007-0460-8","volume":"64","author":"P Mougenot","year":"2008","unstructured":"Mougenot P, Lidove O, Caillaud C, Arnaud P, Papo T (2008) Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance. Eur J Clin Pharmacol 64(6):635\u2013639","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1853_CR41","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/TP.0000000000003224","volume":"105","author":"MLR Wyld","year":"2021","unstructured":"Wyld MLR, De La Mata NL, Masson P, O\u2019Lone E, Kelly PJ, Webster AC (2021) Cardiac mortality in kidney transplant patients: a population-based cohort study 1988\u20132013 in Australia and New Zealand. Transplantation 105(2):413\u2013422","journal-title":"Transplantation"},{"issue":"4","key":"1853_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1432-2277.2008.00824.x","volume":"22","author":"M Cybulla","year":"2009","unstructured":"Cybulla M, Walter KN, Schwarting A, Divito R, Feriozzi S, Sunder-Plassmann G (2009) European FOSIG: kidney transplantation in patients with Fabry disease. Transpl Int 22(4):475\u2013481","journal-title":"Transpl Int"},{"issue":"5","key":"1853_CR43","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, Sirrs S, Mehta A, Elliott PM, Oder D, Watkinson OT, Bichet DG, Khan A et al (2018) Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet 55(5):351\u2013358","journal-title":"J Med Genet"},{"issue":"6","key":"1853_CR44","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E (2021) Fabry disease: the current treatment landscape. Drugs 81(6):635\u2013645","journal-title":"Drugs"},{"issue":"12","key":"1853_CR45","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neusser LP, Rudnicki M, Nordbeck P, Canaan-Kuhl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C et al (2018) Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with fabry disease. J Am Soc Nephrol 29(12):2879\u20132889","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"1853_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, Canaan-Kuhl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C et al (2017) Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med 282(3):241\u2013253","journal-title":"J Intern Med"},{"issue":"5","key":"1853_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ (2019) Migalastat: a review in Fabry disease. Drugs 79(5):543\u2013554","journal-title":"Drugs"},{"key":"1853_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010206","author":"O Azevedo","year":"2020","unstructured":"Azevedo O, Gago MF, Miltenberger-Miltenyi G, Sousa N, Cunha D (2020) Fabry disease therapy: state-of-the-art and current challenges. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22010206","journal-title":"Int J Mol Sci"},{"key":"1853_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121304","author":"V Di Stefano","year":"2021","unstructured":"Di Stefano V, Mancarella M, Camporeale A, Regalia A, Ferraresi M, Pisaniello M, Cassinerio E, Pieruzzi F, Motta I (2021) Migalastat treatment in a kidney-transplanted patient with Fabry disease and N215S mutation: the first case report. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14121304","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"1853_CR50","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/jimd.12228","volume":"43","author":"SJ van der Veen","year":"2020","unstructured":"van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M (2020) Developments in the treatment of Fabry disease. J Inherit Metab Dis 43(5):908\u2013921","journal-title":"J Inherit Metab Dis"},{"key":"1853_CR51","doi-asserted-by":"publisher","first-page":"110779","DOI":"10.1016\/j.biopha.2020.110779","volume":"131","author":"S Kant","year":"2020","unstructured":"Kant S, Atta MG (2020) Therapeutic advances in Fabry disease: the future awaits. Biomed Pharmacother 131:110779","journal-title":"Biomed Pharmacother"},{"key":"1853_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100968","author":"D Hughes","year":"2023","unstructured":"Hughes D, Gonzalez D, Maegawa G, Bernat JA, Holida M, Giraldo P, Atta MG, Chertkoff R, Alon S, Almon EB et al (2023) Long-term safety and efficacy of pegunigalsidase alfa: a multicenter 6-year study in adult patients with Fabry disease. Genet Med. https:\/\/doi.org\/10.1016\/j.gim.2023.100968","journal-title":"Genet Med"},{"key":"1853_CR53","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.ymgmr.2022.100862","volume":"31","author":"C Wanner","year":"2022","unstructured":"Wanner C, Kimonis V, Politei J, Warnock DG, Uceyler N, Frey A, Cornelisse P, Hughes D (2022) Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Mol Genet Metab Rep 31:100862","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"1853_CR54","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","volume":"12","author":"A Khan","year":"2021","unstructured":"Khan A, Barber DL, Huang J, Rupar CA, Rip JW, Auray-Blais C, Boutin M, O\u2019Hoski P, Gargulak K, McKillop WM et al (2021) Lentivirus-mediated gene therapy for Fabry disease. Nat Commun 12(1):1178","journal-title":"Nat Commun"},{"issue":"3","key":"1853_CR55","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40259-013-0032-7","volume":"27","author":"AP Ruiz de Garibay","year":"2013","unstructured":"Ruiz de Garibay AP, Solinis MA, Rodriguez-Gascon A (2013) Gene therapy for fabry disease: a review of the literature. BioDrugs 27(3):237\u2013246","journal-title":"BioDrugs"},{"issue":"4","key":"1853_CR56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B, Presnyak V, Frassetto A, Milton J, Salerno T et al (2019) Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates. Am J Hum Genet 104(4):625\u2013637","journal-title":"Am J Hum Genet"},{"key":"1853_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157782","author":"F Braun","year":"2023","unstructured":"Braun F, Abed A, Sellung D, Rogg M, Woidy M, Eikrem O, Wanner N, Gambardella J, Laufer SD, Haas F et al (2023) Synuclein alpha accumulation mediates podocyte injury in Fabry nephropathy. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI157782","journal-title":"J Clin Invest"},{"issue":"1","key":"1853_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2014","unstructured":"van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE (2014) A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 51(1):1\u20139","journal-title":"J Med Genet"},{"key":"1853_CR59","doi-asserted-by":"crossref","first-page":"100562","DOI":"10.1016\/j.ymgmr.2019.100562","volume":"22","author":"T Sawada","year":"2020","unstructured":"Sawada T, Kido J, Yoshida S, Sugawara K, Momosaki K, Inoue T, Tajima G, Sawada H, Mastumoto S, Endo F et al (2020) Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep 22:100562","journal-title":"Mol Genet Metab Rep"},{"issue":"6","key":"1853_CR60","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","volume":"81","author":"O Lidove","year":"2012","unstructured":"Lidove O, Kaminsky P, Hachulla E, Leguy-Seguin V, Lavigne C, Marie I, Maillot F, Serratrice C, Masseau A, Cherin P et al (2012) Fabry disease The New Great Imposter: results of the French Observatoire in internal medicine departments (FIMeD). Clin Genet 81(6):571\u2013577","journal-title":"Clin Genet"},{"key":"1853_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12914","author":"R Reisin","year":"2017","unstructured":"Reisin R, Perrin A, Garcia-Pavia P (2017) Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract. https:\/\/doi.org\/10.1111\/ijcp.12914","journal-title":"Int J Clin Pract"},{"issue":"6","key":"1853_CR62","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","volume":"360","author":"M Michaud","year":"2020","unstructured":"Michaud M, Mauhin W, Belmatoug N, Garnotel R, Bedreddine N, Catros F, Ancellin S, Lidove O, Gaches F (2020) When and how to diagnose Fabry disease in clinical pratice. Am J Med Sci 360(6):641\u2013649","journal-title":"Am J Med Sci"},{"issue":"3","key":"1853_CR63","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","volume":"126","author":"DP Germain","year":"2019","unstructured":"Germain DP, Arad M, Burlina A, Elliott PM, Falissard B, Feldt-Rasmussen U, Hilz MJ, Hughes DA, Ortiz A, Wanner C et al (2019) The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease-A systematic literature review by a European panel of experts. Mol Genet Metab 126(3):224\u2013235","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1853_CR64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2215\/CJN.09480819","volume":"15","author":"E Svarstad","year":"2020","unstructured":"Svarstad E, Marti HP (2020) The changing landscape of Fabry disease. Clin J Am Soc Nephrol 15(4):569\u2013576","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1853_CR65","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfs526","volume":"28","author":"W Terryn","year":"2013","unstructured":"Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C (2013) Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28(3):505\u2013517","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1853_CR66","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jmd2.12035","volume":"48","author":"J Frabasil","year":"2019","unstructured":"Frabasil J, Durand C, Sokn S, Gaggioli D, Carozza P, Carabajal R, Politei J, Schenone AB (2019) Prevalence of Fabry disease in male dialysis patients: Argentinean screening study. JIMD Rep 48(1):45\u201352","journal-title":"JIMD Rep"},{"issue":"Suppl 4","key":"1853_CR67","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/ndt\/gfu030","volume":"29","author":"E Wuhl","year":"2014","unstructured":"Wuhl E, van Stralen KJ, Wanner C, Ariceta G, Heaf JG, Bjerre AK, Palsson R, Duneau G, Hoitsma AJ, Ravani P et al (2014) Renal replacement therapy for rare diseases affecting the kidney: an analysis of the ERA-EDTA Registry. Nephrol Dial Transplant 29(Suppl 4):iv1\u2013iv8","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1853_CR68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ndt\/gfaa324","volume":"37","author":"A Nagata","year":"2021","unstructured":"Nagata A, Nasu M, Kaida Y, Nakayama Y, Kurokawa Y, Nakamura N, Shibata R, Hazama T, Tsukimura T, Togawa T et al (2021) Screening of Fabry disease in patients with chronic kidney disease in Japan. Nephrol Dial Transplant 37(1):115\u2013125","journal-title":"Nephrol Dial Transplant"},{"key":"1853_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8100396","author":"M Veroux","year":"2020","unstructured":"Veroux M, Monte IP, Rodolico MS, Corona D, Bella R, Basile A, Palmucci S, Pistorio ML, Lanza G, De Pasquale C et al (2020) Screening for Fabry disease in kidney transplant recipients: experience of a multidisciplinary team. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines8100396","journal-title":"Biomedicines"},{"issue":"1","key":"1853_CR70","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13730-020-00510-9","volume":"10","author":"M Minami","year":"2021","unstructured":"Minami M, Mizuma E, Nakahara M, Oda Y, Yoshimine H, Tokunaga K, Mitsuke A, Yamada Y, Enokida H, Masutani K et al (2021) A case of latent heterozygous Fabry disease in a female living kidney donor candidate. CEN Case Rep 10(1):30\u201334","journal-title":"CEN Case Rep"},{"key":"1853_CR71","first-page":"1","volume":"4","author":"LS Paull","year":"2012","unstructured":"Paull LS, Lipinski MJ, Wilson WG, Lipinski SE (2012) Female with Fabry disease unknowingly donates affected kidney to sister: a call for pre-transplant genetic testing. JIMD Rep 4:1\u20134","journal-title":"JIMD Rep"},{"issue":"1","key":"1853_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2215\/CJN.02490607","volume":"3","author":"J Andrade","year":"2008","unstructured":"Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD, Sirrs S (2008) Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3(1):139\u2013145","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1853_CR73","doi-asserted-by":"publisher","first-page":"506","DOI":"10.5414\/CNP75506","volume":"75","author":"EF Wallin","year":"2011","unstructured":"Wallin EF, Clatworthy MR, Pritchard NR (2011) Fabry disease: results of the first UK hemodialysis screening study. Clin Nephrol 75(6):506\u2013510","journal-title":"Clin Nephrol"},{"key":"1853_CR74","doi-asserted-by":"publisher","first-page":"640876","DOI":"10.3389\/fmed.2021.640876","volume":"8","author":"Y Battaglia","year":"2021","unstructured":"Battaglia Y, Fiorini F, Azzini C, Esposito P, De Vito A, Granata A, Storari A, Mignani R (2021) Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis. Front Med (Lausanne) 8:640876","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1853_CR75","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12882-022-02805-8","volume":"23","author":"A Mallett","year":"2022","unstructured":"Mallett A, Kearey PJ, Cameron A, Healy HG, Denaro C, Thomas M, Lee VW, Stark SL, Fuller M, Wang Z et al (2022) The prevalence of Fabry disease in a statewide chronic kidney disease cohort-Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) study. BMC Nephrol 23(1):169","journal-title":"BMC Nephrol"},{"issue":"4","key":"1853_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000184389","volume":"46","author":"D Donati","year":"1987","unstructured":"Donati D, Novario R, Gastaldi L (1987) Natural history and treatment of uremia secondary to Fabry\u2019s disease: an European experience. Nephron 46(4):353\u2013359","journal-title":"Nephron"},{"key":"1853_CR77","doi-asserted-by":"publisher","DOI":"10.1159\/000059903","volume-title":"Hereditary kidney diseases","author":"V Mazzarella","year":"1997","unstructured":"Mazzarella V, Splendiani G, Tozzo C, Tisone G, Pisani F, Iaria G, Casciani CU (1997) Renal transplantation in patients with hereditary kidney disease: our experience. In: Conte F, Meroni M, Battini G, Sessa A (eds) Hereditary kidney diseases, vol 122. Karger, Basel"},{"issue":"10","key":"1853_CR78","doi-asserted-by":"publisher","first-page":"4211","DOI":"10.1016\/j.transproceed.2005.11.021","volume":"37","author":"D Inderbitzin","year":"2005","unstructured":"Inderbitzin D, Avital I, Largiader F, Vogt B, Candinas D (2005) Kidney transplantation improves survival and is indicated in Fabry\u2019s disease. Transplant Proc 37(10):4211\u20134214","journal-title":"Transplant Proc"},{"issue":"3","key":"1853_CR79","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1432-2277.2008.00791.x","volume":"22","author":"J Kleinert","year":"2009","unstructured":"Kleinert J, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K, Voigtl\u00e4nder T, Wallner M, Kramar R, Stummvoll HK et al (2009) Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22(3):287\u2013292","journal-title":"Transpl Int"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01853-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-023-01853-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-023-01853-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:53:43Z","timestamp":1777564423000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/37\/3\/561\/8306639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":79,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s40620-023-01853-z","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest in relation to this research project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No animals were involved in this study. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article did not involve any direct studies with animals or humans, as it is a review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"No formal consent was necessary for this review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}